載入中
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
一般交易時段
US$1.825
+US$0.0386 · +2.16%
盤中時間採用ET。市場資料可能有所延遲。
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
日內區間
目前US$1.825
52週區間
目前US$1.825
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
56
多空交錯
風險
78
高風險
動能
24
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
日內區間
目前US$1.825
52週區間
目前US$1.825
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 311.4萬 USD | 1229.2萬 USD |
| 銷貨成本 | 24萬 USD | 35.2萬 USD | — | — | — |
| 毛利 | −24萬 USD | −35.2萬 USD | — | 311.4萬 USD | 1229.2萬 USD |
| 研究與開發 | 1454萬 USD | 1437.8萬 USD | 1710.7萬 USD | 1788.2萬 USD | 1899.4萬 USD |
| 銷售、一般及管理費用 | 1177.2萬 USD | 1022.4萬 USD | 1177.1萬 USD | 1387.3萬 USD | 1469.8萬 USD |
| 營業費用 | 2607.2萬 USD | 2425萬 USD | 2887.8萬 USD | 3175.5萬 USD | 3369.2萬 USD |
| 折舊和攤銷 | 24萬 USD | 35.2萬 USD | 56.7萬 USD | 90.1萬 USD | 114.4萬 USD |
| 營業利益 | −2631.2萬 USD | −2460.2萬 USD | −2887.8萬 USD | −2864.1萬 USD | −2140萬 USD |
| 淨利 | −2596.7萬 USD | −2413萬 USD | −1741.1萬 USD | 802.7萬 USD | −2845.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年12月30日 | 1:18 | — | — |
股票分割 | 2025年5月27日 | 1:20 | — | — |
股票分割 | 2024年12月4日 | 1:37 | — | — |
股票分割 | 2024年3月6日 | 1:44 | — | — |
股票分割 | 2020年3月27日 | 1:14 | — | — |
已生效 2025年12月30日
1:18
已生效 2025年5月27日
1:20
已生效 2024年12月4日
1:37
已生效 2024年3月6日
1:44
已生效 2020年3月27日
1:14
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
